GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:004593629 | Thyroid | HT | negative regulation of phosphate metabolic process | 54/1272 | 441/18723 | 1.86e-05 | 4.39e-04 | 54 |
GO:00511469 | Thyroid | HT | striated muscle cell differentiation | 39/1272 | 283/18723 | 1.95e-05 | 4.58e-04 | 39 |
GO:004217726 | Thyroid | HT | negative regulation of protein catabolic process | 22/1272 | 121/18723 | 1.97e-05 | 4.60e-04 | 22 |
GO:001056329 | Thyroid | HT | negative regulation of phosphorus metabolic process | 54/1272 | 442/18723 | 1.99e-05 | 4.60e-04 | 54 |
GO:000974329 | Thyroid | HT | response to carbohydrate | 36/1272 | 253/18723 | 2.00e-05 | 4.63e-04 | 36 |
GO:005102810 | Thyroid | HT | mRNA transport | 23/1272 | 130/18723 | 2.04e-05 | 4.68e-04 | 23 |
GO:190390027 | Thyroid | HT | regulation of viral life cycle | 25/1272 | 148/18723 | 2.07e-05 | 4.70e-04 | 25 |
GO:003250725 | Thyroid | HT | maintenance of protein location in cell | 15/1272 | 65/18723 | 2.30e-05 | 5.15e-04 | 15 |
GO:00506708 | Thyroid | HT | regulation of lymphocyte proliferation | 33/1272 | 225/18723 | 2.35e-05 | 5.25e-04 | 33 |
GO:190165324 | Thyroid | HT | cellular response to peptide | 46/1272 | 359/18723 | 2.46e-05 | 5.48e-04 | 46 |
GO:001095228 | Thyroid | HT | positive regulation of peptidase activity | 30/1272 | 197/18723 | 2.63e-05 | 5.84e-04 | 30 |
GO:004873228 | Thyroid | HT | gland development | 53/1272 | 436/18723 | 2.71e-05 | 5.97e-04 | 53 |
GO:00024494 | Thyroid | HT | lymphocyte mediated immunity | 45/1272 | 350/18723 | 2.76e-05 | 6.05e-04 | 45 |
GO:00329447 | Thyroid | HT | regulation of mononuclear cell proliferation | 33/1272 | 227/18723 | 2.82e-05 | 6.13e-04 | 33 |
GO:190288225 | Thyroid | HT | regulation of response to oxidative stress | 19/1272 | 98/18723 | 2.82e-05 | 6.13e-04 | 19 |
GO:001072017 | Thyroid | HT | positive regulation of cell development | 40/1272 | 298/18723 | 2.85e-05 | 6.14e-04 | 40 |
GO:007136425 | Thyroid | HT | cellular response to epidermal growth factor stimulus | 12/1272 | 45/18723 | 3.23e-05 | 6.88e-04 | 12 |
GO:00970664 | Thyroid | HT | response to thyroid hormone | 9/1272 | 26/18723 | 3.25e-05 | 6.90e-04 | 9 |
GO:190236919 | Thyroid | HT | negative regulation of RNA catabolic process | 16/1272 | 75/18723 | 3.51e-05 | 7.35e-04 | 16 |
GO:003297030 | Thyroid | HT | regulation of actin filament-based process | 49/1272 | 397/18723 | 3.65e-05 | 7.57e-04 | 49 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
AR | SNV | Missense_Mutation | | c.2595N>A | p.Asp865Glu | p.D865E | P10275 | protein_coding | deleterious(0) | probably_damaging(0.923) | TCGA-A1-A0SO-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | | SD |
AR | SNV | Missense_Mutation | | c.1912N>A | p.Leu638Met | p.L638M | P10275 | protein_coding | tolerated(0.07) | benign(0.316) | TCGA-A8-A07R-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Ancillary | zoledronic | SD |
AR | SNV | Missense_Mutation | novel | c.1082N>A | p.Ser361Asn | p.S361N | P10275 | protein_coding | tolerated_low_confidence(0.27) | benign(0.015) | TCGA-AC-A8OP-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
AR | SNV | Missense_Mutation | | c.1681N>A | p.Leu561Met | p.L561M | P10275 | protein_coding | deleterious(0.03) | probably_damaging(0.999) | TCGA-BH-A18L-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
AR | SNV | Missense_Mutation | | c.1703C>T | p.Ser568Phe | p.S568F | P10275 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-E9-A1R4-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | 5-fluorouracil | SD |
AR | SNV | Missense_Mutation | novel | c.2642N>A | p.Leu881Gln | p.L881Q | P10275 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-OL-A66K-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
AR | SNV | Missense_Mutation | novel | c.585N>T | p.Gln195His | p.Q195H | P10275 | protein_coding | tolerated_low_confidence(0.13) | benign(0.005) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
AR | SNV | Missense_Mutation | novel | c.2718N>T | p.Lys906Asn | p.K906N | P10275 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
AR | SNV | Missense_Mutation | novel | c.967N>A | p.Glu323Lys | p.E323K | P10275 | protein_coding | tolerated_low_confidence(0.11) | benign(0.265) | TCGA-C5-A1MN-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Chemotherapy | cisplatin | SD |
AR | SNV | Missense_Mutation | | c.2462G>T | p.Gly821Val | p.G821V | P10275 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-EA-A410-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
367 | AR | DRUGGABLE GENOME, NUCLEAR HORMONE RECEPTOR, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR, DRUG RESISTANCE | | FLUOCINOLONE ACETONIDE | FLUOCINOLONE ACETONIDE | |
367 | AR | DRUGGABLE GENOME, NUCLEAR HORMONE RECEPTOR, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR, DRUG RESISTANCE | | 4-CHLOROMERCURIBENZOIC ACID | 4-CHLOROMERCURIBENZOIC ACID | |
367 | AR | DRUGGABLE GENOME, NUCLEAR HORMONE RECEPTOR, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR, DRUG RESISTANCE | agonist | CHEMBL2107067 | TESTOSTERONE UNDECANOATE | |
367 | AR | DRUGGABLE GENOME, NUCLEAR HORMONE RECEPTOR, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR, DRUG RESISTANCE | | DIDECYLDIMETHYLAMMONIUM CHLORIDE | DIDECYLDIMETHYLAMMONIUM CHLORIDE | |
367 | AR | DRUGGABLE GENOME, NUCLEAR HORMONE RECEPTOR, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR, DRUG RESISTANCE | | QUININE SULFATE | QUININE SULFATE | |
367 | AR | DRUGGABLE GENOME, NUCLEAR HORMONE RECEPTOR, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR, DRUG RESISTANCE | | NILUTAMIDE | NILUTAMIDE | |
367 | AR | DRUGGABLE GENOME, NUCLEAR HORMONE RECEPTOR, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR, DRUG RESISTANCE | | RALOXIFENE HYDROCHLORIDE | RALOXIFENE HYDROCHLORIDE | |
367 | AR | DRUGGABLE GENOME, NUCLEAR HORMONE RECEPTOR, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR, DRUG RESISTANCE | | ARN-509 | APALUTAMIDE | |
367 | AR | DRUGGABLE GENOME, NUCLEAR HORMONE RECEPTOR, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR, DRUG RESISTANCE | | CRUFOMATE | CRUFOMATE | |
367 | AR | DRUGGABLE GENOME, NUCLEAR HORMONE RECEPTOR, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR, DRUG RESISTANCE | | 2-AMINOFLURENE | CHEMBL84472 | |